Open AccessMP56-16 EFFICACY AND SAFETY OF TRANSDERMAL OXYBUTYNIN VERSUS ORAL OXYBUTYNIN IN THE MANAGEMENT OF PEDIATRIC NEUROGENIC BLADDER
Author(s) -
Emily Rice,
Laura Watkins,
Gowri Sivalingam,
Maddison Burmaz,
Anna Thetford,
Elizabeth Thomson,
Jane Valentine,
Anna Gubbay,
Gavan Hotana,
Katherine Langdon,
Naeem Samnakay,
Andrew Barker,
Japinder Khosa
Publication year - 2018
Publication title -
the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1016/j.juro.2018.02.1807
Subject(s) - oxybutynin , medicine , transdermal , pharmacology , overactive bladder , alternative medicine , pathology
Anticholinergic medications are the gold standard in pharmacotherapy for neurogenic bladder. The first line agent in Australia is oxybutynin due to cost and accessibility. Oxybutynin is available in both oral and transdermal forms. Oral oxybutynin can be associated with a significant side effect profile in some children. Additionally, compliance may be poor with oral medication due to difficulty in taking tablets in addition to inability to tolerate associated side effects. Transdermal formulations have the potential advantage of ease of use resulting in increased compliance and reduced systemic side effects. effects. CONCLUSIONS
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom